Founded in 2013, Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments and biomarkers for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease.

We have revolutionized ALS research through our innovative ecosystem that fosters collaboration between academia and the pharmaceutical/biotech industry, democratizes ALS research by lowering barriers to work on the disease by providing access to critical research tools and acts as a hub of communication and networking for the worldwide research community. 

In just ten years, we have transformed ALS research landscape with 60% of collaborative projects funded by us leading to ongoing drug discovery programs, launch of 6 clinical trials and 5 biotech startups.